Understanding The Role of Integrin Alpha6beta4 in Cell Adhesion and Migration

Target Name: Integrin alpha6beta4 receptor

NCBI ID: P16316

Integrin alpha6beta4 receptor

Other Name(s): Integrin alpha 6 beta 4 | Integrin alpha-6/beta-4 | Laminin receptor

Understanding The Role of Integrin Alpha6beta4 in Cell Adhesion and Migration

Integrin alpha6beta4 (Integrin alpha 6 beta 4) is a cell-surface protein that is composed of two subunits, alpha6 and beta4. It is a member of the integrin family, which is a large family of transmembrane proteins that play a crucial role in cell -cell adhesion and other cellular processes (1).Integrin alpha6beta4 is expressed in many different tissues and cells, including epithelial cells, endothelial cells, pericytes, and various immune cells.

Integrin alpha6beta4 is involved in many different cellular processes, including cell adhesion, migration, and invasion. It is one of the most widely studied cell-surface proteins, and is a potential drug target and biomarker.

The alpha6 subunit of Integrin alpha6beta4 is 150 amino acids long and contains a heparan sulfate proteoglycan (HSPG) domain, as well as a cytoplasmic domain and a transmembrane domain. The beta4 subunit is 120 amino acids long and contains an N-terminal domain, a central transmembrane domain, and a C-terminal domain.

Integrin alpha6beta4 is a cell-surface protein that is involved in many different cellular processes, including cell adhesion, migration, and invasion.

One of the most well-studied functions of Integrin alpha6beta4 is its role in cell adhesion. Integrin alpha6beta4 is involved in the formation of tight junctions, which are a type of cell-cell adhesion that helps to maintain tissue structure and prevent excessive fluid out of the body.

Integrin alpha6beta4 is also involved in the process of cell migration. When a cell is ready to move, it secretes a signal called the chemotactic factor (CF), which causes the cell to move towards a nearby source of GFP-labeled signaling molecules. is involved in the recognition of the CF signal by its extracellular domain.

Integrin alpha6beta4 is also involved in the process of cell invasion. When a cell is trying to invade a new tissue, it needs to be able to remove its adherens junction, which is a type of tight junction that helps to maintain the integrity of the cell membrane. Integrin alpha6beta4 is involved in the removal of the adherens junction, allowing the cell to invade the new tissue.

In addition to its role in cell adhesion and migration, Integrin alpha6beta4 is also involved in the regulation of cell survival. Studies have shown that Integrin alpha6beta4 can inhibit the activity of the chemotherapy drug taxol, which is commonly used to treat breast cancer.

Integrin alpha6beta4 is also a potential biomarker for some diseases, including cancer. For example, some studies have shown that high levels of Integrin alpha6beta4 are associated with poor prognosis in patients with pancreatic cancer.

In conclusion, Integrin alpha6beta4 is a cell-surface protein that is involved in many different cellular processes, including cell adhesion, migration, and invasion. It is a potential drug target and biomarker for some diseases, including cancer. Further research is needed to fully understand the role of Integrin alpha6beta4 in these processes and its potential as a drug.

Protein Name: Integrin Alpha6beta4 Receptor

The "Integrin alpha6beta4 receptor Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Integrin alpha6beta4 receptor comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets